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S290 Poster Session IIresponse to prior conditioning with pharmacokinetic-targeted IV
busulfan(130-145 mg/m2) and fludarabine (40 mg/m2) x 4 days (t-
IV Bu/Flu) followed by HCT. All were treated with rituximab at
375 mg/m2 on days 1 and 8 after a matched related (n5 7), mis-
matched related (n5 1), matched unrelated(n5 6), or mismatched
unrelated (n5 2) HCT. Two patients received ATG as GVHD
prophylaxis. Median time to neutrophil and platelet engraftment
was 15 and 13 days, respectively. Maximum grades of aGVHD ob-
served were 0 (n5 4), 1(n5 7), 2 (n5 7), and 3 (n5 1). Moderate/
severe cGVHD occurred in only 3/16. With a median F/U of 15
months (range: 2-33), complete response was achieved in 12, per-
sistent residual disease in 3, and progressive disease in 1. CMV re-
activation(n5 8), as well as bacterial (n5 8), fungal (n5 3), and
viral (n5 3) infection did not appear to exceed historical rates with-
out rituximab. After HCT, prolonged lymphopenia was demon-
strated: Median absolute lymphocyte counts (0.84 K/uL)
remained below the reference range through one year. In 5/16 sub-
jects for which B-cell data was available, B-cell lymphopenia per-
sisted to one year after HCT. The addition of rituximab 375 mg/
m2 to t-IV Bu/Flu followed by allogeneic HCT has encouraging
activity in the treatment of lymphoid malignancies. While both ab-
solute and B-cell lymphopenia were observed through one year
after HCT, infectious complications have not exceeded historical
rates.357
THE INCIDENCE OF HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME
(SOS) FOLLOWING A PREPARATIVE REGIMEN OF DOSE TARGETED IN-
TRAVENOUS BUSULFAN AND CYTOXAN AND A GRAFT VERSUS HOST DIS-
EASE PROPHYLACTIC REGIMEN OF TACROLIMUS AND METHOTREXATE:
A SINGLE INSTITUTION EXPERIENCE
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Hepatic sinusoidal obstruction syndrome (SOS) is a common
complication of preparative regimens in the setting of stem cell
transplantation. The use of intravenous Busulfan (Bu), however, re-
sulted in decrease in the incidence of SOS to 8%. The graft-versus-
host-disease (GVHD) prophylactic regimen seems also to impact
the risk of SOS following an ablative transplant. The goal of this
study is to determine the incidence of clinically significant SOS
in a homogenous cohort of patients who received an ablative regi-
men of dose targeted intravenous Busulfan and cytoxan (Bu/Cy),
and received tacrolimus and methotrexate (Tac/MTX) for
GVHD prophylaxis.
Methods: In this retrospective study, patients who received an
ablative regimen of intravenous Bu/Cy, and received Tac/MTX
for GVHD prophylaxis were identified. Data collected include:
age, indication for transplant, disease status at transplant, stem
cell source, date of transplant, date of onset of clinically signifi-
cant SOS, and date and cause of death. Patients who underwent
an ablative regimen of total body irradiation (TBI) and cytoxan
and received the same GVHD prophylactic regimen were used
for comparison.
Results:Between September, 2007 and August, 2009, 34 patients re-
ceived an ablative regimen of intravenous Bu/Cy and GVHD pro-
phylactic regimen of Tac/MTX. In this cohort, age ranged from
25 to 63 years old. Diagnoses were as follows: AML n5 20, MDS
n5 7, CML n5 4, myelofibrosis n5 2, and NHL n5 1. Disease
status at diagnosis was CR1 n5 16, $ CR2 n5 5, relapsed/refrac-
tory n5 2, untreated n5 6, PR n5 3, chronic phase CML n5 2.
In this cohort, only three (8.8%) patients developed clinically signif-
icant SOS. Two patients were diagnosed within 3 weeks of trans-
plant, however, one patient developed biopsy proven SOS 58 days
post transplant. None of the patients in this cohort died of SOS.
In 28 out of 34 patients, Bu pharmacokinetic (PK) studies were
done properly. In two patients the Bu dose was increased and in
one case the dose was decreased. In the comparison cohort, 29 pa-
tients received TBI/Cy conditioning regimen. In this cohort only
one patient (3.4%) developed SOS.
Conclusion:The incidence of SOS in the cohort of patients who re-
ceived dose targeted intravenous Bu/Cy and Tac/MTX for GVHDprophylaxis was comparable to the reported incidence of SOS in lit-
erature and appears to be higher than the incidence of SOS in the
TBI/Cy and Tac/MTX cohort.358
COMORBIDITY SCORE IN ALLOGENEIC MYELOABLATIVE TRANSPLANTS
CONDITIONED WITH FLUDARABINE/I.V. BUSULFAN (FLUBU4)
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The assessment of comorbidity score was previously demon-
strated to predict the risk of transplant related mortality (TRM) in
patients undergoing standard myeloablative allogeneic hematopoi-
etic stem cell transplantation (HSCT). Since Flu/Bu4 regimen has
been associated with limited extra-hematologic toxicity, we analyzed
whether the comorbidity score may still represent a useful tool in
transplant patients conditioned with this regimen. Of 52 consecutive
patients who received a matched HSCT with FluBu4 at our institu-
tion, 50 were evaluable for assessing their pre-transplant comorbid-
ity score according to the initial description (Sorror M et al. Blood
2005, 106:2912). The total dose of I.V. Bu was 12.8 mg/kg in 18 pa-
tients while in the remaining patients a targeted dose was given
(AUC: 4800 mM*min). Patients were divided in three groups: group
A, score 0 (n5 8); group B, score 1-2 (n5 16), group C, score$ 3
(n5 26). The three groups did not differ significantly in age, diagno-
sis, previous lines of chemotherapy, type of donor and targeted vs
standard dose of I.V. Bu. Patients with active acute leukemia at the
time of HSCT were 12% in group A, 18% in group B and 29% in
group C (p5 ns). Thirteen patients (26%) died due to relapse of
their malignancy and 11 (22%) due to transplant-related complica-
tions. TRMwas 12% in group A, 37% in group B and 15% in group
C despite the fact that the rate of acute GVHD grade II-IV was
slightly higher in group C (34%), compared to groups A (12%)
and B (31%). Patients in group C had a trend for higher relapse-re-
latedmortality, 38%, compared to 12%observed in each of the other
groups (p5 0.07). After a median follow-up of 640 days (range: 111-
2065), a greater number of patients were alive and in remission in
group A (75%) (p5 0.04), compared to group B (50%) and C
(34%). In conclusion, a higher comorbidity score correlated with
worse overall survival largely due to increased relapse. However, it
did not predict TRM in patients conditioned with FluBu4.359
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The relative merits of PBSCT versus BMT for children with stan-
dard and high risk hematologicmalignancies remain unclear. In a ret-
rospective single center study, we compared allogeneic peripheral
blood stem cell transplantation (PBSCT) (n5 30) with bonemarrow
transplantation (BMT) (n5 110) in children with acute leukemia be-
tween January 1st, 2001 and September 30th, 2006. Four (13.3%)
PBSCT patients received HLA identical sibling donors versus 38
(34.5%) who received marrow: 15 (50.0%) PBSCT recipients re-
ceived HLA mismatched PBSC versus 10 (9.1%) receiving marrow.
Nine (30.0%) PBSCT patients had an HLA matched unrelated do-
nor versus 49 (44.5%) of marrow recipients. Two PBSCT (6.7%)
were from mismatched unrelated donors versus 13 (11.8%) in the
marrow recipients. The median age for PBSCT was 9 years versus
8 years for BMT. Descriptive statistics were used to summarize the
demographic and medical variables. The unadjusted probabilities
of disease-free survival were estimated using the Kaplan-Meier
method. The association of graft-source and time to each of the
study endpoints was estimated by Cox’s regressionmodel and the oc-
currence of GvHD was included as a time-dependent covariate.
Time to both neutrophil engraftment and platelet independence
